Stellar Pharmaceuticals Inc.

Stellar Pharmaceuticals Inc.

January 04, 2005 14:40 ET

Stellar International Inc. Changes Name to Stellar Pharmaceuticals Inc.


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: STELLAR PHARMACEUTICALS INC.

TSX VENTURE SYMBOL: SLX
OTC Bulletin Board SYMBOL: SLXCF

JANUARY 4, 2005 - 14:40 ET

Stellar International Inc. Changes Name to Stellar
Pharmaceuticals Inc.

LONDON, ONTARIO--(CCNMatthews - Jan. 4, 2005) -

Stock Commences Trading Under New Name and Symbol SLXCF

Stellar International Inc. (TSX VENTURE:SLX) (OTCBB:SLXCF) announced
today that it has changed its name to Stellar Pharmaceuticals Inc. The
Company is a Canadian pharmaceutical developer and marketer of high
quality, cost-effective products for select health care markets. This
name change, which became effective January 1, 2005, is being made so
that the Company's name better reflects its underlying business.

The Company stated that the name change will not affect the validity of
currently outstanding stock certificates. Stellar's current stockholders
will not be required to surrender or exchange any stock certificates
that they now hold. The Company is now trading on the OTC Bulletin Board
under the ticker symbol "SLXCF" and is continuing to trade on the TSX
Venture Exchange under the ticker symbol "SLX".

About Stellar Pharmaceuticals, Inc.

Stellar has developed and is marketing three products in Canada based on
its core polysaccharide technology: NeoVisc®, for the treatment of
osteoarthritis, Uracyst® and the Uracyst® Test Kit, Stellar's
patented technology for the diagnosis and treatment of Interstitial
Cystitis (IC), an inflammatory disease of the urinary bladder wall.
Stellar also has in-licensing agreements for Skelite™ a proprietary
synthetic bone-grafting product and NMP22® BladderChek®, a
proteomics-based diagnostic test for the diagnosis and monitoring of
bladder cancer which are expected to positively impact sales in 2005.

This press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Readers are cautioned
not to place undue reliance on these forward-looking statements. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of risks and uncertainties
impacting the Company's business including increased competition; the
ability of the Company to expand its operations, to attract and retain
qualified professionals, technological obsolescence; general economic
conditions; and other risks detailed time to time in the Company's
filings.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Stellar Pharmeceuticals Inc.
    Peter Riehl
    President & CEO
    (800) 639-0643 or (519) 434-1540
    (519) 434-4382 (FAX)
    or
    Stellar Pharmeceuticals Inc.
    Arnold Tenney
    Chairman
    (416) 587-3200
    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release.